A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer.
Background: Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC). Methods:...
| Publicado en: | Current Oncology Vol. 32; no. 1; pp. 6 - 26 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jan2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=182443208&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 182443208 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Jan2025 vid: 32 iid: 1 pid: 97109 pub: MDPI artinfo: ui: 182443208 10.3390/curroncol32010006 182443208 ppf: 6 ppct: 20 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer. aug: au: Giffoni de Mello Morais Mata, Danilo Pezo, Rossanna C. Chan, Kelvin K. W. Menjak, Ines Eisen, Andrea Trudeau, Maureen affil: Division of Medical Oncology, Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada sug: ab: Background: Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC). Methods: Through a retrospective study of stage I-III HER2-negative BC, using administrative databases, we analyzed a total of 10,634 women treated with adjuvant chemotherapy in Ontario, Canada, between 2009 and 2017. We compared TC versus standardized anthracycline–taxane chemotherapies (ACT and FEC-D). We investigated the overall survival (OS), and explored the incidence of CHF, emergency department (ED) visits and febrile neutropenia. Results: With a median follow-up of 5.5 years, the 5-year analysis showed an increased OS in patients treated with TC, versus those treated with ACT, HR 0.77 (0.63–0.95, p = 0.015). Among ER+ BC, there was an increased OS in patients treated with ACT and FEC-D, versus those treated with TC, HR 0.70 (0.52–0.95, p = 0.021) and HR 0.71 (0.56–0.91, p = 0.007), respectively. There were no substantial differences in CHF, between TC and anthracycline-based treatments. Patients treated with TC and FEC-D had more ED visits, compared to those treated with ACT. Conclusion: Our study shows that anthracycline–taxane regimens were the most commonly prescribed adjuvant chemotherapy options in HER2-negative BC. Women who received ACT had the lowest OS, likely due to their unfavorable pathology. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|